Marc Hemmelder

Marc Hemmelder is a Full Professor in the Department of Internal Medicine at Erasmus MC, a leading academic medical center in the Netherlands. His work is integral to advancing clinical nephrology and transplant medicine through rigorous research and large-scale trials.

His research focuses on improving outcomes in patients with chronic kidney disease and kidney transplant recipients. Key areas include immunosuppressive strategies, vaccine efficacy in immunocompromised patients, and pharmacological interventions for cardiorenal protection. His work often involves multicenter collaborations and randomized controlled trials.

The recent publications highlight a strong trend in clinical intervention studies, particularly around modulating immunosuppression to enhance vaccine responses and evaluating SGLT2 inhibitors like dapagliflozin in advanced kidney disease. These studies reflect a translational approach bridging pharmacology, immunology, and patient-centered outcomes.

Marc Hemmelder is actively contributing to high-impact research, as evidenced by publications in journals such as Clinical Infectious Diseases and Nephrology Dialysis Transplantation. While no specific awards or grants are listed, his leadership in major trials like RECOVAC and Renal Lifecycle indicates significant recognition and funding support within the nephrology community.

He is part of a robust research network at Erasmus MC, collaborating with experts in transplant immunology, infectious diseases, and clinical pharmacology. His involvement in large investigator-led consortia underscores his role in shaping evidence-based practices in nephrology and transplantation.